Suchergebnisse - "Diabetic Nephropathies/physiopathology [MeSH]"

Is GFR decline induced by SGLT2 inhibitor of clinical importance?

Autoren: Günes-Altan, Merve Bosch, Agnes Striepe, Kristina et al.

Quelle: Cardiovasc Diabetol
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-12 (2024)

Schlagwörter: Male, Time Factors, Linagliptin, Pulse Wave Analysis, Kidney, 03 medical and health sciences, Vascular Stiffness, 0302 clinical medicine, Glucosides, Diseases of the circulatory (Cardiovascular) system, Humans, Insulin, Diabetic Nephropathies, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors, Aged, PWV, Research, Middle Aged, Metformin, 3. Good health, Treatment Outcome, Diabetes Mellitus, Type 2, RC666-701, GFR decline, Female, Drug Therapy, Combination, Benzhydryl Compounds/therapeutic use [MeSH], Kidney/drug effects [MeSH], Sodium-Glucose Transporter 2 Inhibitors/therapeutic use [MeSH], Aged [MeSH], Diabetic Nephropathies/diagnosis [MeSH], Diabetes Mellitus, Type 2/physiopathology [MeSH], Sodium-Glucose Transporter 2 [MeSH], Diabetes Mellitus, Type 2/drug therapy [MeSH], Metformin/therapeutic use [MeSH], Kidney/physiopathology [MeSH], Hypoglycemic Agents/adverse effects [MeSH], Male [MeSH], Hypoglycemic Agents/therapeutic use [MeSH], Glucosides/adverse effects [MeSH], Clinical Relevance [MeSH], Drug Therapy, Combination [MeSH], SGLT2 inhibitors, Glomerular Filtration Rate/drug effects [MeSH], Sodium-Glucose Transporter 2 Inhibitors/adverse effects [MeSH], Diabetes Mellitus, Type 2/diagnosis [MeSH], Female [MeSH], Linagliptin/therapeutic use [MeSH], Benzhydryl Compounds/adverse effects [MeSH], Biomarkers/blood [MeSH], Humans [MeSH], Insulin [MeSH], Linagliptin/adverse effects [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Time Factors [MeSH], Diabetic Nephropathies/physiopathology [MeSH], Glucosides/therapeutic use [MeSH], Diabetic Nephropathies/drug therapy [MeSH], Pulse Wave Analysis [MeSH], Vascular Stiffness/drug effects [MeSH], Glomerular Filtration Rate

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38811998
https://doaj.org/article/16e1093b68244e548ee9caeec43f6782
https://repository.publisso.de/resource/frl:6506955

Knockout of vascular smooth muscle EGF receptor in a mouse model prevents obesity-induced vascular dysfunction and renal damage in vivo

Autoren: Christian Stern Barbara Schreier Alexander Nolze et al.

Quelle: Diabetologia

Schlagwörter: 0301 basic medicine, Serum Response Factor, Myocytes, Smooth Muscle, Vascular Remodeling, Diet, High-Fat, Article, Muscle, Smooth, Vascular, Cell Line, Mice, 03 medical and health sciences, Animals, Humans, Diabetic Nephropathies, Obesity, Aorta, Mice, Knockout, 2. Zero hunger, ddc:610, 0303 health sciences, Actins, 3. Good health, ErbB Receptors, HEK293 Cells, Aorta/metabolism [MeSH], Diabetic Nephropathies/metabolism [MeSH], Epidermal growth factor receptor, Diabetes Mellitus, Type 2/physiopathology [MeSH], Cell Line [MeSH], Aorta/physiopathology [MeSH], Muscle, Smooth, Vascular/physiopathology [MeSH], Hyperglycemia/physiopathology [MeSH], Diabetic Angiopathies/metabolism [MeSH], Vascular dysfunction, Diabetic Nephropathies/genetics [MeSH], Obesity/metabolism [MeSH], Obesity/physiopathology [MeSH], Renal damage, Myocytes, Smooth Muscle [MeSH], Diabetes mellitus, Humans [MeSH], ErbB Receptors/genetics [MeSH], Muscle, Smooth, Vascular/metabolism [MeSH], rho-Associated Kinases/metabolism [MeSH], Animals [MeSH], Diabetic Angiopathies/physiopathology [MeSH], Diet, High-Fat [MeSH], Mice, Knockout [MeSH], Diabetic Nephropathies/physiopathology [MeSH], Mice [MeSH], Serum response factor, Hyperglycemia/metabolism [MeSH], HEK293 Cells [MeSH], Serum Response Factor/metabolism [MeSH], Vascular Remodeling [MeSH], Actins/metabolism [MeSH], Signal Transduction [MeSH], Diabetic Angiopathies/genetics [MeSH], Diabetes Mellitus, Type 2/metabolism [MeSH], EGFR, Diabetes Mellitus, Type 2, Hyperglycemia, Diabetic Angiopathies, Signal Transduction

Dateibeschreibung: application/pdf

Zugangs-URL: https://link.springer.com/content/pdf/10.1007/s00125-020-05187-4.pdf
https://pubmed.ncbi.nlm.nih.gov/32548701
https://link.springer.com/article/10.1007/s00125-020-05187-4
https://link.springer.com/content/pdf/10.1007/s00125-020-05187-4.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476975
https://www.scilit.net/article/c51b7abf74983e6f379a3c2caad16beb?action=show-references
https://pubmed.ncbi.nlm.nih.gov/32548701/
https://opendata.uni-halle.de/handle/1981185920/38486?locale=de
https://repository.publisso.de/resource/frl:6469026

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine

Autoren: Manuel Korn Agnes Bosch Dennis Kannenkeril et al.

Quelle: Cardiovasc Diabetol
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-8 (2021)

Schlagwörter: Male, Renal Plasma Flow, Insulin Glargine, Linagliptin, Benzhydryl Compounds/therapeutic use [MeSH], Sodium-Glucose Transporter 2 Inhibitors/therapeutic use [MeSH], Type 2 diabetes, Renal, Aged [MeSH], Diabetic Nephropathies/diagnosis [MeSH], Insulin Glargine/adverse effects [MeSH], Diabetes Mellitus, Type 2/drug therapy [MeSH], Hemodynamics/drug effects [MeSH], Dipeptidyl-Peptidase IV Inhibitors/therapeutic use [MeSH], Metformin/therapeutic use [MeSH], Original Investigation, Hypoglycemic Agents/adverse effects [MeSH], Male [MeSH], Metformin/adverse effects [MeSH], Hypoglycemic Agents/therapeutic use [MeSH], Glucosides/adverse effects [MeSH], Drug Therapy, Combination [MeSH], Glomerular Filtration Rate/drug effects [MeSH], Diabetic Nephropathies/prevention, Sodium-Glucose Transporter 2 Inhibitors/adverse effects [MeSH], Diabetes Mellitus, Type 2/diagnosis [MeSH], Diabetic Nephropathies/etiology [MeSH], Female [MeSH], Linagliptin/therapeutic use [MeSH], Benzhydryl Compounds/adverse effects [MeSH], Intraglomerular, Diabetes Mellitus, Type 2/complications [MeSH], Humans [MeSH], Linagliptin/adverse effects [MeSH], Prospective Studies [MeSH], Renal Plasma Flow/drug effects [MeSH], Insulin Glargine/therapeutic use [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Time Factors [MeSH], Diabetic Nephropathies/physiopathology [MeSH], Glucosides/therapeutic use [MeSH], Hemodynamics, Germany [MeSH], Dipeptidyl-Peptidase IV Inhibitors/adverse effects [MeSH], 03 medical and health sciences, 0302 clinical medicine, Glucosides, Germany, Diseases of the circulatory (Cardiovascular) system, Humans, Hypoglycemic Agents, Diabetic Nephropathies, ddc:610, Prospective Studies, Benzhydryl Compounds, Aged, Dipeptidyl-Peptidase IV Inhibitors, Middle Aged, Metformin, 3. Good health, Diabetes Mellitus, Type 2, RC666-701, Drug Therapy, Combination, Female, Glomerular Filtration Rate

Dateibeschreibung: application/pdf

Zugangs-URL: https://cardiab.biomedcentral.com/track/pdf/10.1186/s12933-021-01358-8
https://pubmed.ncbi.nlm.nih.gov/34481498
https://doaj.org/article/9b8533fc41d14d86a46ea53eb65ce82e
https://link.springer.com/article/10.1186/s12933-021-01358-8
https://link.springer.com/content/pdf/10.1186/s12933-021-01358-8.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418746/
https://cardiab.biomedcentral.com/articles/10.1186/s12933-021-01358-8
https://opus4.kobv.de/opus4-fau/files/18118/s12933-021-01358-8.pdf
https://repository.publisso.de/resource/frl:6462949